CLEC11A

Across TCGA pan-cancer cohorts, CLEC11A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC11A data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLEC11A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CLEC11A expression acts as an unfavorable survival marker.

LUAD, LSCC, and PDAC are the cancer types where CLEC11A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.333	0.917	.005	35	view →
LSCC	OS	Quartile	All	0.704	0.955	.005	26	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	DFS	Quartile	III,IV	0.078	0.740	.038	7	view →
HNSC	DFS	Median	IV	0.569	0.779	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC11A–LUAD (DFS)

Open the LUAD breakdown →